Notícias

Franklin Biotechnology Discovery has a much higher 13% five-year annualized return than a biotech index ETF’s 5.3%

Retiring at 55 sounds like freedom, but seven years without a paycheck or Social Security creates a funding gap that destroys most portfolios before the first benefit check ever arrives. The yield tier you choose now determines whether you cross that bridge or fall through it.

Franklin Biotechnology Discovery has a much higher 13% five-year annualized return than a biotech index ETF’s 5.3%

Johnson & Johnson (NYSE:JNJ) continues to stand out as a dividend stock for investors who value dependable income and a long track record of growth. In April 2026, the company raised its dividend by 3.1%, bringing the quarterly payment to $1.34, or $5.36 a year. It was the company’s 64th consecutive year of dividend increases, […]

J&J raises 2026 outlook after second-quarter sales rise 6.6% to $25.31 billion.

The safest Vanguard funds can help you through a volatile market by adding stability to your portfolio at low cost.

These four low-cost Vanguard dividend and income funds have all earned high praise from Morningstar, and they offer attractive yields.

Johnson & Johnson (NYSE: JNJ) received FDA clearance for its MONARCH QUEST 3 bronchoscopy system, a software update to its robotic assisted bronchoscopy platform. The update introduces AI powered tools for procedure planning and lung nodule segmentation within Johnson & Johnson's MedTech portfolio. The clearance expands Johnson & Johnson's capabilities in minimally invasive diagnostics and treatment in robotic assisted bronchoscopy. New digital ecosystem features are designed to support...

Dividend growth ETFs offer investors a steadily growing stream of passive income and exposure to quality companies.

J&J's immunology and neuroscience businesses are emerging as key growth engines, with new drugs helping to offset Stelara's loss of exclusivity.

Colgate-Palmolive Company (NYSE:CL) is often overlooked when investors discuss established dividend stocks. Names such as Coca-Cola, Procter & Gamble, and Johnson & Johnson tend to dominate those conversations. Colgate has a track record that deserves to be mentioned alongside them. It is a Dividend King, with 63 consecutive years of dividend increases and uninterrupted dividend payments […]

While the market chases momentum trades and AI multiples, a small group of blue-chip dividend compounders has quietly raised its payouts for generations and continues doing so in 2026. These five names carry the streaks, the cash flow, and the brand moats to keep rewarding patient investors well into next year.

Generating $210,000 a year in dividends sounds impossible until you break the portfolio into three distinct yield buckets, each with its own risk profile and capital requirement. The math is brutally simple, but most investors build the wrong blend and wonder why their income stagnates.

The MONARCH platform provides flexible, robotically assisted visualisation and airway access for bronchoscopic procedures.

The market seems to have its pharma giants ranked in a peculiar order, leaving one of the group's fastest-growing performers trading at a middle-of-the-pack multiple rather than the group high.

Liquidia's Yutrepia is fueling rapid growth, but patent litigation, competition and heavy product dependence weigh on its outlook.

The biosimilar drag on Johnson & Johnson stock is shrinking, and the business underneath it is already growing at a double-digit pace.

Stock Market Today: The Dow Jones index drops, but the Nasdaq rises as memory-chip stocks Micron and Sandisk rally sharply.

The yield you chase to replace a salary can quietly destroy the purchasing power you built to protect. Before you settle on a number, understand what the tradeoff between yield and dividend growth actually costs you over a decade.

Pharma's 2026 recovery puts Bayer, Eli Lilly and Johnson & Johnson in focus as innovation and M&A offset pricing and patent headwinds.

Some companies have handed investors a bigger paycheck every single year for more than six decades, surviving every recession and rate shock along the way. Five of them look particularly compelling right now, and one trades at a price not seen in over a year.

Johnson & Johnson shares have quietly delivered a huge gain in 2026 so far, up more than 25%. The gain has similarly shown strong outperformance relative to the S&P 500, with recent results driving positive momentum post-earnings.

AbbVie's growth engine is firing on all cylinders, but on its latest earnings call, analysts focused on whether the company can defend its turf and execute on its next big pipeline bet.

Johnson & Johnson has delivered a 68.9% total return over the past 5 years, yet its valuation picture is split, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to upside while market multiples lean the other way. Over 5 years, Johnson & Johnson has returned 68.9%, which puts the recent share price near the upper end of its longer term journey. Pipeline progress in areas such as major depressive disorder therapies and new medical technologies like surgical robotics can...

AbbVie's neuroscience franchise posts strong first-half growth, with Vyalev accelerating and tavapadon poised to add another potential growth driver.

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

In the Large-Cap Pharmaceuticals industry, LLY, J&J and BAYRY are worth watching as the industry shows a strong recovery.

The clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.

Fifty-plus years of unbroken dividend raises sounds like a floor, but not every Dividend King deserves a permanent seat in your portfolio right now. Five do, and one of them is actually trading at a discount that long-term income investors rarely get handed.

Medicare's IRMAA surcharge punishes a single dollar of overage with a full bracket jump and no phase-in, yet some retirees collect six figures annually and never trigger it. The strategy depends on how income is classified, not how much arrives.